Adagene (ADAG) vs Compass Therapeutics (CMPX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Adagene (ADAG) has outperformed Compass Therapeutics (CMPX) over the past year, gaining 41.2% versus a loss of 71.7%. Over five years, CMPX leads with a -68.2% price change compared with -76.0% for ADAG. Adagene is the larger company by market cap ($188.7 million vs $183.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | CMPX |
|---|---|---|
| Share price | $2.81 | $1.02 |
| Market cap | $188.67M | $183.69M |
| 1-day change | -4.10% | +2.19% |
| YTD return | +48.68% | -81.01% |
| 1-year return | +41.21% | -71.75% |
| 5-year return | -75.98% | -68.22% |
| EPS (TTM) | $-0.37 | $-0.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.85 | $6.88 |
| 52-week low | $1.30 | $0.829 |
| Distance from 52-week high | -42.06% | -85.17% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +252.67% | +434.31% |
| Average volume | 246.37K | 4.08M |
| Shares outstanding | 67.14M | 180.09M |
| Employees | 128 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADAG has outperformed CMPX by 113.0 percentage points over the past year.
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
ADAG vs CMPX FAQ
Which is bigger, Adagene or Compass Therapeutics?
Adagene (ADAG) is larger, with a market capitalization of $188.67M compared with $183.69M for Compass Therapeutics (CMPX).
Which stock has performed better over the past year, ADAG or CMPX?
ADAG returned +41.21% over the past 12 months, compared with -71.75% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and Compass Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Adagene and Biotechnology: Biological Products (No Diagnostic Substances) for Compass Therapeutics.